نتایج جستجو برای: memantine

تعداد نتایج: 1420  

2012
Laura E. Pope Kerri A. Schoedel Cynthia Bartlett Edward M. Sellers

BACKGROUND AND OBJECTIVE Dextromethorphan/quinidine (DMQ) is the first agent indicated for the treatment of pseudobulbar affect. Dextromethorphan, the active ingredient, is a low-affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. This study evaluated the potential for a drug-drug interaction (DDI) of DMQ with memantine, which is also an NMDA receptor antagonist. METHODS ...

Journal: :JAMA 2014
Maurice W Dysken Mary Sano Sanjay Asthana Julia E Vertrees Muralidhar Pallaki Maria Llorente Susan Love Gerard D Schellenberg J Riley McCarten Julie Malphurs Susana Prieto Peijun Chen David J Loreck George Trapp Rajbir S Bakshi Jacobo E Mintzer Judith L Heidebrink Ana Vidal-Cardona Lillian M Arroyo Angel R Cruz Sally Zachariah Neil W Kowall Mohit P Chopra Suzanne Craft Stephen Thielke Carolyn L Turvey Catherine Woodman Kimberly A Monnell Kimberly Gordon Julie Tomaska Yoav Segal Peter N Peduzzi Peter D Guarino

IMPORTANCE Although vitamin E and memantine have been shown to have beneficial effects in moderately severe Alzheimer disease (AD), evidence is limited in mild to moderate AD. OBJECTIVE To determine if vitamin E (alpha tocopherol), memantine, or both slow progression of mild to moderate AD in patients taking an acetylcholinesterase inhibitor. DESIGN, SETTING, AND PARTICIPANTS Double-blind, ...

Journal: :The Clinical journal of pain 2007
Nektarios Sinis Niels Birbaumer Sylvia Gustin Anja Schwarz Sabine Bredanger Stephan Thomas Becker Klaus Unertl Hans-Eberhard Schaller Max Haerle

OBJECTIVES Recent studies have confirmed the contribution of the central nervous system (CNS) to the pathogenesis of Complex Regional Pain Syndrome (CRPS), because animal models of neuropathic pain syndromes demonstrate an overexpression of N-methyl-D-aspartate-receptors in the CNS. The aim of this work was to study the influence of a central acting drug-the N-methyl-D-aspartate receptor antago...

Journal: :Journal of Alzheimer's disease : JAD 2011
Jörg B Schulz Michael Rainer Hans-Hermann Klünemann Alexander Kurz Stefanie Wolf Kati Sternberg Frank Tennigkeit

The present study evaluated the effects of once-daily memantine (20 mg) treatment on cognition and communication in patients with moderate to severe Alzheimer's disease (AD). In a multicenter, single-arm open-label study, outpatients diagnosed with AD (MMSE < 20; n = 97) were titrated from 5 mg to 20 mg once-daily memantine over 4 weeks. Once-daily memantine treatment (20 mg) was then continued...

Journal: :The Journal of pharmacology and experimental therapeutics 2003
Gino Villetti Marco Bergamaschi Franco Bassani Pier Tonino Bolzoni Marisa Maiorino Claudio Pietra Ivano Rondelli Philippe Chamiot-Clerc Michele Simonato Mario Barbieri

N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) is a novel low-affinity, noncompetitive N-methyl-d-aspartate receptor antagonist. The current study compared the antinociceptive effects of CHF3381 with those of gabapentin and memantine in in vitro and in vivo models of pain. In isolated rat spinal cord, CHF3381 and memantine, but not gabapentin, produced similar inhibition of the wind-up pheno...

Journal: :Journal of Alzheimer's disease : JAD 2012
David Wilkinson Nick C Fox Frederik Barkhof Ravinder Phul Ole Lemming Philip Scheltens

The primary objective of this study was to evaluate the rate of total brain atrophy (TBA) with serial magnetic resonance imaging (MRI), using the Brain Boundary Shift Integral (BBSI), in patients with probable Alzheimer's disease (AD) over the course of 52 weeks of treatment with memantine or placebo. This was a multi-national, randomized, double-blind, placebo-controlled, fixed-dose 1-year stu...

2016
S. R. T. Veerman P. F. J. Schulte J. D. Smith L. de Haan

BACKGROUND Dysfunction of neuroplasticity due to N-methyl-d-aspartate (NMDA) receptor hypofunction may be a causal factor for memory and executive dysfunctioning in schizophrenia. Deregulation of NMDA transmission in the prefrontal cortex may also explain negative and positive symptoms. Clozapine augmentation with memantine targets altered NMDA receptor-mediated neurotransmission in schizophren...

Journal: :Journal of Alzheimer's disease : JAD 2011
Martine Vercelletto Claire Boutoleau-Bretonnière Christelle Volteau Michèle Puel Sophie Auriacombe Marie Sarazin Bernard-François Michel Philippe Couratier Catherine Thomas-Antérion Patrice Verpillat Audrey Gabelle Véronique Golfier Evelyne Cerato Lucette Lacomblez

We tested the efficacy and tolerability of one-year treatment with memantine (10 mg bid) in behavioral variant frontotemporal dementia (bvFTD). BvFTD patients aged 45 to 75 years, with a Mini-Mental Status Examination (MMSE) score ≥19, were enrolled in a national, randomized, double-blind, placebo-controlled (DBPC), Phase II trial. The primary endpoint was the CIBIC-Plus (Clinician's Interview-...

2009
Shawn E. Kotermanski Jon W. Johnson

N-Methyl-D-aspartate receptors (NMDARs) mediate interneuronal communication and are broadly involved in nervous system physiology and pathology (Dingledine et al., 1999). Memantine, a drug that blocks the ion channel formed by NMDARs, is a widely prescribed treatment of Alzheimer’s disease (Schmitt, 2005; Lipton, 2006; Parsons et al., 2007). Research on memantine’s mechanism of action has focus...

2010
Jean-Michel Arrang

2 a) Running Title : Memantine activates histamine neurons in vivo. This article has not been copyedited and formatted. The final version may differ from this version. ABSTRACT We previously reported that some NMDA-receptor antagonists enhanced histamine neuron activity in rodents. Here, we have investigated the effects of memantine, an NMDA-receptor antagonist used for the treatment of Alzheim...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید